tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Robyn Karnauskas, 283 are a BUY (83.98%), 52 are a HOLD (15.43%), 2 are a SELL (0.59%).
Analyst Robyn Karnauskas, carries an average stock price target met ratio of 51.03% that have a potential upside of 42.2% achieved within 346 days. Previously, Robyn Karnauskas worked at TRUIST.
Robyn Karnauskasās has documented 705 price targets and ratings displayed on 44 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on TRML, Tourmaline Bio at 10-Sep-2025.
Analyst best performing recommendations are on FATE (FATE THERAPEUTICS).
The best stock recommendation documented was for FATE (FATE THERAPEUTICS) at 1/5/2023. The price target of $7 was fulfilled within 1 day with a profit of $4 (36.36%) receiving and performance score of 363.64.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
$251
$17.09 (7.31%)
$205
5 days ago
(02-Oct-2025)
15/16 (93.75%)
$17.09 (7.31%)
300
Buy
$270
$36.09 (15.43%)
$195
21 days ago
(16-Sep-2025)
2/3 (66.67%)
$49.19 (22.28%)
121
Buy
$235
$1.09 (0.47%)
$200
22 days ago
(15-Sep-2025)
14/14 (100%)
$18.74 (8.67%)
483
Buy
$245
$11.09 (4.74%)
$210
23 days ago
(14-Sep-2025)
16/17 (94.12%)
$27.39 (12.59%)
244
Buy
$260
$26.09 (11.15%)
$240
26 days ago
(11-Sep-2025)
8/9 (88.89%)
$41.66 (19.08%)
463
Which stock is Robyn Karnauskas is most bullish on?
Which stock is Robyn Karnauskas is most reserved on?
What Year was the first public recommendation made by Robyn Karnauskas?
